Skip to main content

Page R. Hubben

Associate

[email protected]

+1.617.348.1808

Share:

Page advises public companies on capital-raising transactions, SEC reporting and corporate governance.  Page also counsels public and private companies on a broad range of executive compensation and equity compensation arrangements and programs, including equity and incentive plans and related tax, corporate and securities law concerns.

Page concentrates her practice on the life sciences and technology sectors, including representing pharmaceutical, biotech and medical device companies.

She represents issuers in IPOs, de-SPAC and reverse merger transactions, follow-on public offerings, ATM offerings, registered directs and PIPEs.  Page also has experience representing buyers and sellers in mergers and acquisitions, spinoffs and private equity investments.  As part of her practice advising public companies, Page helps clients navigate corporate governance and securities compliance obligations, ESG matters, Nasdaq and NYSE listing requirements, proxy advisory firm policies, and rules regarding disclosure of director and executive compensation.

Page also has an active pro bono practice. She has represented clients in applications for political asylum in the United States and represented asylum candidates in bond hearings.

Education

  • New York University School of Law (JD)
  • Northwestern University (BA)

Viewpoints

Securities & Capital Markets Viewpoints Thumbnail

Preparation for 2021 Fiscal Year-End SEC Filings and 2022 Annual Shareholder Meetings

January 18, 2022 | Advisory | By Megan Gates, John Condon, Anne Bruno, Melanie Ruthrauff Levy, Daniel T. Kajunski, Cynthia Larose, Breton Leone-Quick, Page R. Hubben

Read about key regulatory and other developments, including board diversity and other ESG matters, which public companies need to consider as they prepare for their fiscal year-end SEC filings and 2022 annual shareholder meetings.
Read more